Introducing the New Mount Sinai Tisch Cancer Center

For nearly two decades, Mount Sinai provided exceptional cancer care and conducted groundbreaking research through The Tisch Cancer Institute, recognized in 2015 as a National Cancer Institute (NCI)-Designated Cancer Center. In October 2025, it received Comprehensive Cancer Center designation from the NCI, part of the National Institutes of Health. This is the highest recognition given cancer centers in the United States, achieved by consistently delivering results in patient care and research.

With this designation, The Tisch Cancer Institute has been renamed the Mount Sinai Tisch Cancer Center (TCC). Encompassing a vast network of cancer clinical care and research, the TCC is the umbrella for all things cancer at the Mount Sinai Health System, including well-known points of service such as the Dubin Breast Center and the Derald H. Ruttenberg Treatment Center. It will also incorporate a new cancer hospital—the Mount Sinai Tisch Cancer Hospital—slated for operation in the next few years.

“This branding change emphasizes we provide the best, most complete care at Mount Sinai,” says Ramon E. Parsons, MD, PhD, Director of the Mount Sinai Tisch Cancer Center. “For a patient, cancer care is often complex and challenging. Accessing that care through TCC means a tight, collaborative approach with the best cancer doctors, researchers, clinical trial investigators, and non-cancer specialists—all working together to provide comprehensive care at convenient sites throughout the Mount Sinai Health System.”

The Comprehensive Cancer Center designation also brings with it more than $3 million in annual funding to support TCC’s research and innovation.

A Meteoric Rise

The TCC got its beginnings as The Tisch Cancer Institute, established in 2008 through the generosity of James S. and Merryl H. Tisch. Since then, it has recruited more than 200 prominent scientists and physicians with faculty appointments at the Icahn School of Medicine at Mount Sinai. The TCC has also attracted more than $590 million in funding from the NCI since 2015.

In 2015, The Tisch Cancer Institute earned Clinical Cancer Center status from the NCI, a significant mark of excellence in scientific leadership, groundbreaking research, and patient care. Applying for the highest designation of Comprehensive Cancer Center requires a 10-year wait.

“Once we became eligible to apply, in September 2024, we did so immediately,” says Dr. Parsons. “We were confident that our application would attest to the depth and breadth of our research, both research in progress and research that has already produced groundbreaking advancements in patient care. Our ability to translate research findings into clinical applications and address the unique needs of the communities we serve was clearly established.”

In October 2025, the NCI confirmed official designation of The Tisch Cancer Institute (now the Mount Sinai Tisch Cancer Center) as a Comprehensive Cancer Center. It is one of just 73 NCI-Designated Cancer Centers—57 Comprehensive Cancer Centers, 9 Clinical Cancer Centers, and 7 Basic Laboratory Cancer Centers—in 37 states and the District of Columbia.

New York has the second highest number of NCI-Designated Cancer Centers (8), after California (10).

A New Cancer Hospital

Part of TCC’s goal for delivering optimal care is a dedicated, state-of-the-art cancer hospital. In September 2025, the New York State Public Health and Health Planning Council, which reviews and approves capital and construction projects, gave full approval for the construction of the Mount Sinai Tisch Cancer Hospital.

The thoughtfully designed hospital will feature four floors with approximately 18 single-bed rooms on each floor along with innovative clinical spaces intended to ease transitions between various stages of treatment. Construction is slated to begin in early 2026.

“These new capabilities will ensure the highest quality care with the latest equipment and specialists across multiple disciplines working together under one roof,” says Dr. Parsons. “With TCC gaining Comprehensive Cancer Center status and a new cancer hospital on the horizon, the future for cancer clinical care and research at the Mount Sinai Health System promises continued excellence and the best possible outcomes for our patients.”